Innorna, a clinical‑stage biotech company advancing RNA medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IN026 ...
IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's proprietary mRNA-LNP platform.HONG KONG SAR ...
At the New York Historical, an exhibition reminds us that the sari is a living art form, an heirloom, a document, and a ...
Ongoing security tension and nighttime sirens are disrupting the sleep cycles of millions of Israelis, increasing anxiety and health risks.
Genethon, a pioneer and leader in gene therapy for rare diseases, unveiled results at the MDA Conference in Orlando confirming the long-term efficacy of its GNT0004 gene therapy in Duchenne muscular ...
Sjögren-Larsson syndrome (SLS) constitutes a rare genetic disorder manifesting as a complex neurocutaneous condition characterised by congenital ichthyosis, progressive neurological impairment and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results